Background and Objectives: Many clinical practice guidelines (CPGs) on the treatment of schizophrenia have been updated. Aiming to review current CPGs, focusing specifically on long-actin...
Objective: Phase 3 trials have demonstrated the efficacy and safety of esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) for treatment-resistant depression (TRD...
Objective: This post hoc analysis assessed (1) whether the first-week incidence of adverse events (AEs) considered most commonly linked to the duration of the post-dose monitoring period ...
Abstract: Purpose: Paliperidone palmitate once-every-3-months (PP3M) is a long-acting injectable antipsychotic indicated for adults with schizophrenia adequately treated (AT) with once-mo...
Abstract: Background: Although long-acting injectable antipsychotics (LAIs) are often reserved for patients with chronic schizophrenia, emerging evidence suggests that LAIs may reduce the...